Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant

  1. Venkata Viswanadh Edara
  2. Katharine Floyd
  3. Lilin Lai
  4. Meredith Gardner
  5. William Hudson
  6. Anne Piantadosi
  7. Jesse J. Waggoner
  8. Ahmed Babiker
  9. Rafi Ahmed
  10. Xuping Xie
  11. Kumari Lokugamage
  12. Vineet Menachery
  13. Pei-Yong Shi
  14. Mehul S. Suthar
  15. for the COVID-19 Neutralization Study Group

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Antibody responses against the SARS-CoV-2 Spike protein correlate with protection against COVID-19. Serum neutralizing antibodies appear early after symptom onset following SARS-CoV-2 infection and can last for several months. Similarly, the messenger RNA vaccine, mRNA-1273, generates serum neutralizing antibodies that are detected through at least day 119. However, the recent emergence of the B.1.1.7 variant has raised significant concerns about the breadth of these neutralizing antibody responses. In this study, we used a live virus neutralization assay to compare the neutralization potency of sera from infected and vaccinated individuals against a panel of SARS-CoV-2 variants, including SARS-CoV-2 B.1.1.7. We found that both infection- and vaccine-induced antibodies were effective at neutralizing the SARS-CoV-2 B.1.1.7 variant. These findings support the notion that in the context of the UK variant, vaccine-induced immunity can provide protection against COVID-19. As additional SARS-CoV-2 viral variants continue to emerge, it is crucial to monitor their impact on neutralizing antibody responses following infection and vaccination.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2021.02.02.21250799: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Ethics statement: For samples collected at Emory University, collection and processing were performed under approval from the University Institutional Review Board (IRB #00001080 and #00022371).
    Consent: Adults ≥18 years were enrolled who met eligibility criteria for SARS-CoV-2 infection (PCR confirmed by a commercially available assay) and provided informed consent.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Cells were incubated with an anti-SARS-CoV spike primary antibody directly conjugated to biotin (CR3022-biotin) for 1 hour at room temperature.
    anti-SARS-CoV spike
    suggested: None
    CR3022-biotin
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    EHC-083E was isolated from a residual nasopharyngeal swab collected from a patient in Atlanta, GA in March 2020 (SARS-CoV-2/human/USA/GA-EHC-083E/2020), plaque purified on Vero cells, propagated on Vero cells and sequenced.
    Vero
    suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)
    Viral titers were determined by focus-forming assay on VeroE6 cells.
    VeroE6
    suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
    Software and Algorithms
    SentencesResources
    The NIAID served as the trial sponsor and made all decisions regarding the study design and implementation.
    NIAID
    suggested: (NIAID, RRID:SCR_016598)
    The FRNT-50 titers were interpolated using a 4-parameter nonlinear regression in GraphPad Prism 8.4.3.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04283461Active, not recruitingSafety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1…

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2021.02.02.21250799 on medRxiv